Klebsiella pneumoniae (16%) with a median MINO MIC of 1 μg/L. 68% of patients received combination therapy. Treatment success was observed in 71 patients (63%). Patients with treatment failure had a higher median Charlson Comorbidity Index (5 vs 3; P = 0.026), SOFA score (7 vs 5; P = 0.028), and were more likely to have underlying leukemia or lymphoma (39% vs 7%; P < 0.001). No differences were seen in primary or secondary outcomes between combination and monotherapy regimens. MICs had no impact on failure outcome, 30-day mortality or 90-day recurrence (all P > 0.05); however, MICs ≤ 2 μg/L were associated with increased risk of treatment failure (34% vs 12%; P = 0.021). In a multivariable analysis, vasopressor use (OR 2.79, 95% CI 1.05-7.41, P = 0.04) and underlying leukemia/lymphoma (OR 4.49, 95% CI 1.26-15.95; P = 0.02) were associated with increased risk of treatment failure.

Conclusion. MINO MIC impacted resistance, but did not correlate with treatment failure, mortality or recurrence. Severity of illness and comorbidities but not choice of MINO may be associated with clinical failures.

Disclosures. All authors: No reported disclosures.

2440. Weight-Adjusted Pipercillin-Tazobactam (PIP/TAZ) Therapy in Obese Patients vs. Optimized Doses in Non-obese Patients: A Retrospective Cohort Study
Sarah Moore, PharmD; Chad Knorder, PharmD and S. Christian Cheatham, PharmD,Pharmacy, Franciscan Health Indianapolis, Indianapolis, Indiana, 2Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, Indianapolis, Indiana, 3Pharmacy, Franciscan St. Francis Health, Indianapolis, Indiana

Session: 250. Treatment of AMR Infections
Saturday, October 6, 2018: 12:30 PM

Background. Dose optimized PIP/TAZ utilizing prolonged infusion has been shown to improve clinical outcomes. Previous pharmacokinetic studies of these prolonged infusion PIP/TAZ doses that achieve adequate time above minimum inhibitory concentration (T>MIC) in non-obese patients do not achieve similar concentrations in obese patients. Due to this higher doses are necessary in obese patients to achieve adequate T>MIC. Our institution utilizes weight-based dose optimization of PIP/TAZ in obese patients. The purpose of this study was to investigate clinical outcomes and adverse events with these dosing strategies compared with optimized doses in non-obese patients.

Methods. A retrospective single-center cohort study was conducted in patients ≥18 years old with culture-confirmed non-urinary tract Pseudomonas aeruginosa infections. Patients with positive cultures and PIP/TAZ treatment ≥24 hours were classified in groups as obese (≥120 kg) or non-obese (<120 kg).

Results. 44 patients were studied in each arm with mean age 56 ± 13.8 and 65 ± 17.5, median weight 141 [132-170] and 77 [65-99] and median BMI 48 [40.5-56.2] and 26.4 [21.8-29.7] in the obese and non-obese groups respectively. Outcomes in obese compared with non-obese included composite clinical cure/improvement 86.4% and 77.2%, length of stay 8 and 10 days, ICU length of stay 10 and 8 days, hospital mortality 9.1% and 11.3%, 30 day mortality 15.9% and 18.2%, respectively. Adverse events in obese and non-obese groups occurred at 34.1% and 27.3% including AKI at 27% and 16% and thrombocytopenia at 7.1% and 12.8%, respectively. PIP/TAZ was discontinued due to safety concerns in 1 obese patient and 2 non-obese patients.

Conclusion. Weight-adjusted PIP/TAZ doses in obese patients produce similar clinical outcomes to optimized doses in non-obese patients.

Disclosures. All authors: No reported disclosures.
Background. Infections due to extended spectrum β-lactamase (ESBL) producing bacteria are problematic due to the association with worse outcomes and limited treatment options. Carbapenems (CBPs) remain the drugs of choice for these infections due to evidence of a mortality benefit and the mixed clinical efficacy associated with piperacillin/tazobactam (PTZ) despite often reported in vitro activity. While definitive treatment for these infections has been well defined, evidence for appropriate empiric therapy remains inconclusive. Rapid molecular assays capable of identifying ESBL markers may aid in switching to appropriate definitive therapy sooner and spare empiric carbapenem use.

Methods. This multicenter retrospective study at 9 sites at Baylor Scott & White Health included patients with a positive blood culture with ESBL-producing bacteria identified by rapid molecular assay from January 1, 2014 to September 22, 2017 and were empirically prescribed either PTZ or a CBP. Patients were excluded if they continued PTZ for more than 24H after identification or did not receive a CBP for definitive therapy. Categorical data were analyzed using the Fisher’s exact test and continuous data were evaluated using the t-test and Wilcoxon rank-sum test.

Results. 117 patients met inclusion criteria of which 66 and 51 received empiric PTZ or CBPs, respectively. Baseline characteristics were similar between the groups, including suspected source of bacteremia, prior hospital stay, prior antibiotic therapy, history of positive non-blood ESBL culture, ICU admission, and time to ESBL identification. There was no difference in hospital mortality (3% vs. 7.8%, P = 0.4), hospital length of stay (6.1 vs. 5.9%, P = 0.88), ICU length of stay (4.7 vs. 3.3%, P = 0.39) or recurrent ESBL bacteremia (7.6 vs. 7.8%, P = 0.99) between those that received PTZ or a CBP for initial treatment, respectively.

Conclusion. This study in patients with ESBL bacteremia showed similar outcomes when treated empirically with PTZ or a CBP. In the era of rapid molecular assays, these results suggest that empiric PTZ use and avoidance of empiric CBP therapy in the first 24H of infection can be considered until a microbiological diagnosis is confirmed.

Disclosures. All authors: No reported disclosures.

2443. Searching for the Optimal Treatment Regimen for Metallo-β-Lactamase Producing Enterobacteriaceae: Aztreonam Plus Ceftazidime-Avibactam vs. Aztreonam Plus Meropenem–Vaborbactam

Mark Biagi, PharmD1 and Eric Wenzler, PharmD2; 1University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, 2College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois

Session: 250. Treatment of AMR Infections
Saturday, October 6, 2018: 12:30 PM

Background. Pathogens harboring metallo-β-lactamase (MBL) enzymes pose a large threat to public health. Aztreonam (ATM) is not hydrolyzed by MBLs but is inactivated by other β-lactamases, which are often co-harbored in MBL-producers. Ceftazidime/avibactam (CAZ/AVI) and meropenem/vaborbactam (MER/VBR) are novel β-lactam/β-lactamase inhibitors (BLI/BLI) with potent activity against serine β-lactamase producing Enterobacteriaceae. Combining ATM with BLI/BLI agents may provide activity against Enterobacteriaceae producing serine and MBLs.

Methods. Two clinical E. coli isolates were used. MICs were determined in triplicate and modal values were reported. Time kill analyses were performed in triplicate at standard inoculum (108). Each agent was tested alone and in combination at either ¼, ½, 1, 2, 4× MIC based on susceptibility. Bactericidal activity was ≥log2 reduction in CFU/mL from the starting inoculum. Synergy was ≥log2 reduction in CFU/mL compared with the most active agent alone. Antagonism was ≥2 log2 increase in CFU/mL compared with the most active agent alone.

Results. Genotypic/phenotypic susceptibilities are in Table 1. Against EC-1, ATM alone at 1×MIC had no activity. When combined with CAZ/AVI or MER/VBR, respectively, synergy was observed with average log2 decrease in CFU/mL at 24 hours of 3.92 and 5.04 (Figure 1a). Synergy seemed to be driven solely by the addition of the BLI as ATM/CAZ and ATM/MER did not demonstrate synergy (Figure 1a). Against EC-2, ATM alone at 1/4×MIC showed no activity (Figure 1b). Combining ATM with either CAZ/AVI or MER/VBR did not improve the activity or demonstrate synergy (Figure 1b).

Conclusion. There were no significant differences in activity or synergy observed between the combinations of ATM with either CAZ/AVI or MER/VBR against serine- and MBL-producing E. coli. Synergy appears to be driven by the ATM-BLI combinations, with ATM/AVI demonstrating more consistent synergy than ATM/VBR. Further studies including more isolates and combinations are warranted.

Disclosures. E. Wenzler, Melinta Therapeutics: Speaker’s Bureau, Speaker honorarium.

2444. Incidence of Daptomycin Toxicity Among Patients With Vancomycin-Resistant Enterococcus Blood Stream Infections

Maria X Bueno Rios, MD1; Luis A Shimose, MD2; Vasilos Athans, PharmD, BCPPS3; Stephanie Bass, PharmD4; Joshua Ottos, MPH, MLS (ASCP)5; Manshi Li, MS6; Xiaofeng Wang, PhD7; Ashujit Duggal, MD, MPH, MS8; Sandra S. Richter, MD9; Christopher Kovacs, MD1; Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, 2Department of Critical Care Medicine, Cleveland Clinic, Cleveland, Ohio, 3Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, 4Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, 5Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio

Session: 250. Treatment of AMR Infections
Saturday, October 6, 2018: 12:30 PM

Background. Daptomycin (DAP) is a lipopeptide antibiotic and is first-line treatment for infections caused by Vancomycin-resistant Enterococcus (VRE). DAP is considered a safe antimicrobial agent, most commonly causing elevation of CKP. The historical incidence of DAP toxicity reported in the literature is low, ranging between 3 to 9%. We aim to describe the incidence of DAP toxicity among patients with VRE blood stream infection (BSI).

Methods. This is a retrospective cohort study conducted in a tertiary hospital in Cleveland, Ohio. We included all consecutive adult patients diagnosed with VRE BSI treated with DAP between November 2011 and January 2015. Patients were grouped based on dose of DAP received (Group 1: ≤56 mg/kg and Group 2 ≥ 8 mg/kg). Patient data were obtained from the microbiology department database, pharmacy information technology services and electronic medical records (EMR) (Table 1).

Results. During the study period, a total of 217 patients with VRE BSI were treated with DAP. (Table 1) The number of patients that received DAP dose of ≤56 mg/kg was 192 (88%), compared with 25 patients that received a DAP dose of 28 mg/kg (12%). The total incidence of DAP toxicity was present in only 3 patients (1.4%) and of those, only 2 patients developed CPK elevation leading to rhabdomyolysis requiring discontinuation of DAP (Maximum CPK value was 3142 U/L and 987 U/L for each case). The other patient developed a rash thought to be secondary to DAP. Of note, all 3 patients that developed DAP toxicity, received doses of ≤56 mg/kg.

Conclusion. In this retrospective cohort study of patients with VRE BSI treated with DAP, the incidence of DAP toxicity was only 3 cases out of 217 patients. All of these patients received doses of ≤56 mg/kg of DAP. This is lower than what is reported in the literature. DAP was well tolerated and the development of side effects did not seem to be related to the dose.